– Detection of breast cancer through a blood test: Syantra will present the first data from the International Identify Breast Cancer (IDBC) study at the 13th European Conference on Breast Cancer

CALGARY, AB, Nov. 8, 2022 /PRNewswire/ — Syantra, a precision healthcare company that is changing the way cancer is detected and treated, will present IDBC study results at the 13th European Conference on Cancer in Mama, to be held in Barcelona, ​​Spain, from November 16 to 18, 2022.

“We are very pleased to have been selected by the Scientific Committee of the 13th EBCC for a poster session. Our results will contribute to the field’s understanding of how whole blood screening can be applied in cancer detection and treatment,” he said. Kristina Rinker, PhD. “We look forward to discussing the latest results and engaging with stakeholders in advancing cancer detection and treatment.”

Professor Nigel Bundred, Surgical Oncologist, Manchester University NHS Foundation Trust, Wythenshawe Hospital, will present the study data during the poster presentation session.

“The results of the study are very promising. Although breast cancer screening saves lives, many women’s breast cancers go undetected. This is especially true of young women with dense breast tissue, which can make the breast cancer difficult to see on a mammogram,” said Professor Bundred. “More sensitive tests are needed to detect cancer earlier, when it may be easier to treat. We are pleased to share the data, which supports the role of blood testing as a complement to current imaging methods for breast cancer detection. “

Please join Syantra at the stand

As well as stopping by our exhibitor booth, attend our speaker’s presentation and peruse our scientific poster.

Presentation Details

Session Type: Poster Session Date/Time: November 16, 2022, 13:30pm – 14:20pm CET (GMT 1) Location: Dedicated Poster Exhibition AreaSpeaker: Professor Nigel Bundred, MD, FRCSummary: Link

About Syntra

Syantra is a precision healthcare company that is changing the way cancer is detected and treated. Its flagship product, Syantra DXTM Breast Cancer, is a high-throughput, minimally invasive blood test for the detection of breast cancer.

For more information, visit: www.syantra.com Media Inquiries: info@syantra.com

Photo – link

View original content: enlace